Potential role of medicinal mushrooms in breast cancer treatment: Current knowledge and future perspectives

International Journal of Medicinal Mushrooms

Volumn 7, Issue 1-2, 2005, Pages 141-155

  Petrova, Roumyana D ^a,b   Wasser, Solomon P ^a   Mahajna, Jamal A ^b   Denchev, Cvetomir M ^c   Nevo, Eviatar ^a  

^a UNIVERSITY OF HAIFA   (Israel)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^c INSTITUTE OF BIODIVERSITY AND ECOSYSTEM RESEARCH   (Bulgaria)

Author keywords

Breast cancer; Medicinal mushrooms; Nuclear factor kappa B (NF B); Polysaccharide protein complexes; Polysaccharides; Secondary metabolites

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; ACTIVE HEXOSE CORRELATED COMPOUND; AGARICUS BISPORUS EXTRACT; AGARICUS BRASILIENSIS EXTRACT; ANTINEOPLASTIC AGENT; CORDYCEPS OPHIOGLOSSOIDES EXTRACT; CYCLOSPORIN A; ESTROGEN RECEPTOR; GANODERAL; GANODERENIC ACID; GANODERIC ACID; GANODERMIC ACID; GANODEROL; GENISTEIN; GRIFOLA FRONDOSA EXTRACT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INONOTUS OBLIQUUS EXTRACT; LENTINAN; LENTINUS EDODES EXTRACT; LEUCOAGARICUS AMERICANUS EXTRACT; LUCIDENIC ACID; LUCIDONE; PACLITAXEL; PANEPOXIDONE; PHENOL DERIVATIVE; PHYTOESTROGEN; PLANT EXTRACT; PLEUROTUS OSTREATUS EXTRACT; POLYSACCHARIDE; PROGESTERONE RECEPTOR; SPARASSIS CRISPA EXTRACT; TAMOXIFEN; TRAMETES VERSICOLOR EXTRACT; TRITERPENOID; UFT; UNCLASSIFIED DRUG;

AGARICUS BISPORUS; AGARICUS BRASILIENSIS; AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; CULTURAL ANTHROPOLOGY; DRUG ISOLATION; DRUG TARGETING; ETHNOLOGY; FRUIT; GENE EXPRESSION; GRIFOLA FRONDOSA; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INONOTUS OBLIQUUS; LENTINUS EDODES; LEUCOAGARICUS AMERICANUS; MEDICINAL PLANT; MUSHROOM; MYCELIUM; NONHUMAN; PLEUROTUS OSTREATUS; RACE; REVIEW; SIDE EFFECT; SOCIAL ASPECT; SPARASSIS CRISPA; TOXICITY; TRAMETES VERSICOLOR; TREATMENT OUTCOME; UNITED STATES;

AGARICUS BISPORUS; BASIDIOMYCOTA; GANODERMA LUCIDUM; GRIFOLA FRONDOSA; INONOTUS OBLIQUUS; LENTINULA EDODES; LEUCOAGARICUS AMERICANUS; PLEUROTUS OSTREATUS; SPARASSIS CRISPA; TRAMETES VERSICOLOR;

EID: 20944442568     PISSN: 15219437     EISSN: None     Source Type: Journal    
DOI: 10.1615/IntJMedMushr.v7.i12.140     Document Type: Review

References (102)

1. Aoki T. 1984. Lentinan. In: Immune Modulation Agents and Their Mechanisms, Fenichel R. L. and Chirgis M. A., eds., Immunol Stud, 25, pp. 62-77.
2. Biswas D. K., Cruz A. P., Gansberger E., and Pardee A. B. 2000. Epidermal growth factor-induced nuclear factor kB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Med Sci (PNAS), 97(15), 8542-8547.
3. Biswas D. K., Dai S. C., Cruz A., Weiser B., Graner E., and Pardee A. B. 2001. The nuclear factor kB (NF-kB): A potential therapeutic target for estrogen receptor negative breast cancers. Med Sci (PNAS), 98, 10386-10391.
4. Biswas D. K., Martin K. J., McAlister C., Cruz A. P., Graner E., Dai S., and Pardee A. B. 2003. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kB activation. Cancer Res, 63, 290-295.
5. Brodie A., Quing L., and Nakamura J. 1997. Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol, 61, 281-286.
6. Cao Y. and Karin M. 2003. NF-kB in mammary gland development and breast cancer. J Mamm Gland Biol Neopl, 8(2), 215-223.
7. Chihara G. 1992. Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev Biol Stand, 77, 191-197.
8. Chihara G., Hamuro J., Maeda Y. Y., Arai Y., and Fukuoka F. 1970. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Singer (an edible mushroom). Cancer Res, 30, 2776-2781.
9. Dugourd C., Gervais M., Corvol P., and Monnot C. 2003. Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation. Hypertension, 41, 882-890.
10. Ebina T. and Fujimiya Y. 1998. Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biother, 11(4), 259-265.
11. Erkel G., Anke T., and Sterner O. 1996. Inhibition of NF-kB activation by paneropoxydone. Biochem Biophys Res Commun, 226, 214-221.
12. Fisher M. and Yang L. X. 2002. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res, 22(3), 1737-1754.
13. Fugimoto S. and Furue H. 1984. Clinical evaluation of Schizophyllan adjuvant immunohemotherapy for patients with resectable gastric cancer: a randomised controlled trail. Jpn J Surg, 14, 286-292.
14. Fujimiya Y., Suzuki Y., Katahura R., and Ebina T. 1999. Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill. Anticancer Res, 19, 113-118.
15. Furne H. 1985. Clinical evaluation of Schizophyllan (SPG) in gastric cancer-randomized controlled studies. Int J Immunol, 7, 333-336.
16. Furue H., Kitoh I., and Hattori T. 1981. Phase III study of Lentinan. Jpn J Cancer Chemother, 8, 944-960.
17. Gao Y. H., Zhou S. F., Chen G. L., Dai X. H., and Ye J. X. 2002. A phase I/II study of a Ganoderma lucidum extract (Gonopoly) in patients with advanced cancer. Int J Med Mushr, 4, 207-214.
18. Grube B. J., Eng E. T., Kao Y.-C., Kwon A., and Chen S. 2001. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr, 131, 3288-3293.
19. Halpern G. M. and Miller A. H. 2002. Medicinal Mushrooms. Ancient Remedies for Moderm Ailments. M. Evans and Company, New York, 172 pp.
20. Han S. B., Lee C. W., Jeon Y. J., Hong N. D., Yoo I. D., Yang K-H., and Kim H. M. 1999. The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacol, 41, 157-164.
21. Helbig G., Christopherson K. W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K. D., Broxmeyer H. E., and Nakshatri H. 2003. NF-kB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine recetor CXCR4*. J Biol Chem, 287(24), 21631-21638.
22. Hishida I., Nanba H., and Kuroda H. 1988. Antitumor activity exhibited by orally administrated extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull, 36(5), 1819-1827.
23. Hobbs C. 1995. Medicinal Mushrooms: An Exploration of Tradition, Healing and Culture. Botanica Press, Santa Cruz. 251 pp.
24. Hu H., Ahn N. S., Yang X., Lee Y. S., and Kang K. S. 2002. Ganoderma lucidum extracts induce cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int Cancer, 102(3), 250-253.
25. Iino Y., Yokoe T., Maemura M., Horiguchi J., Takei H., Ohwada S., and Morishita Y. 1995. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res, 15(6B), 2907-2912.
26. Ikekawa T., Nakanishi M., Uehara N., Chihara G., and Fukuoka F. 1968. Antitumor action of some Basidiomycetes, especially Phellinus linteus. Jpn J Cancer Res (GANN), 59, 155-157.
27. Jong S. C. and Birmingham J. M. 1992. Medicinal benefits of the mushroom Ganoderma. Adv Appl Microbiol, 37, 101-134.
28. Jong S. C. and Donovick R. 1989. Antitumor and antiviral substances from fungi. Adv Appl Microbiol, 34, 183-261.
29. Kahlos K., Kangas L., and Hiltunen R. 1987. Antitumor activity of some compounds and fractions from an n-hexane extract of Inonotus obliquus. Acta Pharmacol Fennica, 96, 33-40.
30. Karin M. and Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: The control of NF-[k]B activity. Ann Rev Immunol, 18, 621-663.
31. Karin M., Cao Y., Greten F. R., and Li Z. W. 2002. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2, 301-310.
32. Kawagishi H., Okamura K., Kobayashi F., and Kinjo N. 2004. Estrogenic substances from the mycelia of medicinal fungus Cordyceps ophioglossoides (Ehrh.) Fr. (Ascomycetes). Int J Med Mushr, 6, 249-251.
33. Kidd P. M. 2000. The use of mushroom glucans and proteoglycans in cancer treatment. Alt Med Rev, 5(1), 4-27.
34. Kim H. M., Han S. B., Oh G. T., Kim Y. H., Hong D. H., Hong N. D., and Yoo I. D. 1996. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Int J Immunopharmacol, 18(5), 295-303.
35. Kim D. S., Jeong H. J., Bhat K. P., Park S. Y., Kang S. H., Yoo E. H., Lee M., Lee H. W., Krueger R. J., and Kim D. S. 2000. Aromatase and sulfatase inhibitors from Lepiota americana. Planta Med, 66, 78-79.
36. Kimura Y., Tojima H., and Fukase S. 1994. Clinical evaluation of sizofiran as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol, 511, 192-195.
37. Komatsu N., Okubo S., Kikumoto S., Kimura K., Saito S., and Sakaki S. 1969. Host mediated antitumor action of schizophyllan, a glucan produced by Schizophyllum commune. Jpn J Cancer Res, 60, 137-144.
38. Kuiper G. G. J. M., Carlsson B., Grandien J., Enmark E., Häggblad J., Nilsson S., and Gustafsson J-Å. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of the estrogen receptors α and β. Endocrinol, 138, 863-870.
39. Lamkanfi M., Kalai M., Saelens X., Declercq W., and Vandenabeele P. 2004. Caspase-1 activates nuclear factor of the k-enhancer in B cells independently of its enzymatic activity. J Biol Chem, 279(23), 24785-24793.
40. Li X. and O'Malley B. W. 2003. Unfolding the action of progesterone receptors. Minireview. J Biol Chem, 278(41), 39261-39264.
41. Liotta L. A. 2001. In breast-cancer patients, secondary tumours often form in the lungs and bone marrow, for example, but rarely in the kidneys. The explanation for this bias involves soluble attractant molecules called chemokines. Nature, 410, 24-25.
42. Liu J. X. and Zhou J. Y. 1993. Phase II clinical trail for PSP capsules. PSP International Symposium, Fudan University Press, Shanghai.
43. Lorenzen K. and Anke T. 1998. Basidiomycetes as a source for new bioactive natural products. Curr Organic Chem, 2, 329-364.
44. Lykkesfeldt A. E. 1996. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol, 35, 9-14.
45. Madrid L. V., Mayo M. W., Reuther J. Y., and Baldwin Jr. A. S. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kB through utilization of the IkB kinase and activation of the mitogen-activated protein kinase p38*. J Biol Chem, 276(22), 18934-18940.
46. Matsuoka H., Seo Y., Wakasugi H., Saito T., and Tanoda H. 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res, 17, 2751-2756.
47. Matsushita K., Kuramitsu Y., Ohiro Y., Obara M., Kobayashi M., Li Y.-Q., and Hosokawa, M. 1998. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anti-Cancer Drugs, 9, 343-350.
48. Mattila P., Könkö K., Eurola M., Pihlava J-M., Astola J., Vahteristo L., Hietaniemi V., Kumpulainen J., Valtonen M., and Piironen V. 2001. Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms. J Agric Food Chem, 49, 2343-2348.
49. Medina D., Sivaraman L., Hilsenbeck S. G., Coneely O., Ginger M., Rosen J., and O'Malley B. W. 2001. Mechanisms of hormonal prevention of breast cancer. Ann NY Acad Sci, 925, 23-35.
50. Mizuno T. 2000. Development of an antitumor biological response modifier from Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetidae) (Review). Int J Med Mushr, 2, 19-33.
51. Mizuno T. 2002. Medicinal properties and clinical effects of culinary-medicinal mushroom Agaricus blazei Murrill. (Agaricomycetidae) (Review). Int J Med Mushr, 4, 299-312.
52. Mizuno T., Zhuang C., Abe K., Okamoto H., Kiho T., Ukai S., Leclerc S., and Meijer L. 1999. Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetidae). Int J Med Mushr, 1, 301-316.
53. Nakamura T., Akiyama Y., Matsugo S., Uzuka Y., Shibata K., and Kawagishi H. 2003. Purification of caffeic acid as an antioxidant from submerged culture mycelia of Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetidae). Int J Med Mushr, 5, 163-167.
54. Nakazato H., Koike A., and Ito T. 1994. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet, 343, 1122-1126.
55. Nakshatri H., Bhat-Nakshatri P., Martin D. A., Goulet Jr. R. J., and Sledge Jr. G. W. 1997. Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Mol Cell Biol, 17, 3629-3639.
56. Nanba H. 1995. Results of non-controlled clinical study for various cancer patients using maitake-D-fraction. Explore, 6, 19-21.
57. Nanba H. 1997a. Maitake D-fraction: healing and preventive potential for cancer. J Orthomol Med, 12, 43-49.
58. Nanba H. 1997b. Effect of Maitake D-fraction on cancer prevention. Ann NY Acad Sci, 883, 204-207.
59. Natarajan K., Singh S., Burke Jr. T. B., Grunberger D., and Aggarwal B. B. 1996. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kB. Proc Natl Acad Sci USA, 93, 9090-9095.
60. Ohno N., Nameda S., Harada T., Miura N. N., Adachi Y., Nakajima M., Yoshida K., Yoshida H., and Yadomae T. 2003. Immunomodulating activity of a β-glucan preparation, SCG, extracted from a culinary-medicinal mushroom, Sparasis crispa Wulf. : Fr. (Aphyllophoromycetidae), and application to cancer patients. Int J Med Mushr, 5, 359-368.
61. Osborne C. T., Bardou V., Hopp T. A., Chamness G. C., Hilsenbeck S. G., Fuqua S. A. W., Wong J., Allred D. C., Clark G. M., and Schiff R. 2003. Role of estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst, 95, 353-361.
62. Ossowski L. and Lopez M. R. 1996. Proteolytic enzymes in cancer invasion. Introduction. Enzyme Protein, 49, 5-6.
63. Pahl H. 1999. Activators and target genes of Rel/NF-kB transcription factors. Oncogene, 18, 6853-6866.
64. Pan Q., Bao L. W., and Merajver S. D. 2003. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkB signaling cascade. Mol Cancer Res, 7, 701-706.
65. Philips A., Chalbos D., and Rochefort H. 1993. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem, 268, 1403-1408.
66. Power R. F., Mani S. K., Codina J., Conneely O. M., and O'Malley B. W. 1991. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science, 254, 1636-1639.
67. Richer J. K., Jacobsen B. M., Manning N. G., Abel M. G., Wolf D. M., and Horwitz K. B. 2002. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem, 277, 5209-5218.
68. Romieu-Mourez R., Landesman-Bollag E., Seldin D. C., Traish A. M., Mercurio F., and Sonenshein E. 2001. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kB in breast cancer. Cancer Res, 61, 3810-3818.
69. Rowan N. J., Smith J. E., and Sullivan R. 2003. Immunomodulatory activities of mushroom glucans and polysaccharide-protein complexes in animals and humans (A review). Int J Med Mushr, 5, 95-110.
70. Sakagami H. and Aoki T. 1991. Induction of immunopotentation activity by a protein bound polysaccharide PSK (Review). Anticancer Res, 11, 993-1000.
71. Sakagami H. and Takeda M. 1993. Diverse biological activity of PSK (Krestin), a protein-bound polysaccharide from Coriolus versicolor. In: Mushroom Biology and Mushroom Products, Chang S. T., Buswell J. A., and Chiu S. W., eds. Chinese University Press, Hong Kong, pp. 237-245.
72. Samanta A. K., Huang H. J., Bast Jr. R. C., and Liao W. S.-L. 2004. Overexpression of MEKK3 confers resistance to apoptosis through activation of NF-kB*. J Biol Chem, 279(9), 7576-7583.
73. Sekiguchi J. and Gaucher G. M. 1979. Isoepoxydon, a new metabolite of the patulin pathway in Penicillium urticae. Biochem J, 182(2), 445-453.
74. Shin Y., Tamai Y., and Terazawa M. 2000. Chemical constituents of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetidae) III: A new triterpene, 3β,22,25-trihydroxy-lanosta-8-ene from sclerotia. Int J Med Mushr, 2, 201-207.
75. Shotwell J. B., Hu S., Medina E., Abe M., Cole R., Crews C. M., and Wood J. L. 2000. Efficient stereoselective synthesis of isopanepoxidone and panepoxidone: a re-assignment of relative configuration. Tetrahedron Lett, 41, 9639-9643.
76. Sliva D., Labarrere C., Slivova V., Sedlak M., Lloyd F. P. Jr., and Ho N. W. Y. 2002. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun, 298(4), 603-612.
77. Sliva D., Sedlak M., Slivova V., Valachovicova T., Lloyd F. P. Jr., and Ho N. W. Y. 2003. Biologic activity of Ganoderma lucidum for the inhibition of highly invasive breast and prostate cancer cells. J Altern Complement Med, 9(4), 491-497.
78. Smith J. E., Rowan N. J., and Sullivan R. 2002. Medicinal mushrooms: their therapeuthic properties and current medical usage with special emphasis on cancer treatments. Cancer Research UK. University of Strathclyde, Glasgow. 256 pp.
79. Sugimachi K., Inokuchi K., and Matsuura H. 1984. Hormone conditional cancer chemotherapy for recurrent breast cancer prolongs survival. Jpn J Surg, 14, 217-221.
80. Taguchi T. 1983. Effects of Lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer. Jpn J Cancer Res (GANN), 10(2), 387-393.
81. Taguchi T., Furure H., Kimura T., Kondo T., Hattori T., Ito F., and Ogawa N. 1985. End-point result of a randomised controlled study on the treatment of gastrointestinal cancer with a combination of Lentinan and chemotherapeutic agents. Excerp Medic, 1985, 151-165.
82. Talorete T. P. N., Isoda H., and Maekawa T. 2002. Agaricus blazei (Class Basidiomycotina) aqueous extract enhances the expression of c-Jun protein in MCF7 cells. J Agricult Food Chem, 50, 5162-5166.
83. Tekmal R., Ramachandra N., Gubba S., Durgam V. R., Mantione J., Toda K., Shizuta Y., and Dillehay D. 1996. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res., 56, 3180-3185.
84. This P., De la Rochefordiere A., Clough K., Fourquet A., Magdelenat H., and The Breast Cancer Group of the Institute Curie. 2001. Phytoestrogens after breast cancer. Endocr Relat Cancer, 8, 129-134.
85. Toi M. and Hottori T. 1992. Randomised adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. Cancer, 70, 2475-2483.
86. Tsai M.-J. and O'Malley B. W. 1994. Molecular mechanisms of action of steroid/thyroid receptor super-family members. Ann Rev Biochem, 63, 451-486.
87. Watabe M., Hishikawa K., Takayanagi A., Shimizu N., and Nakaki T. 2004. Caffeic acid phenetyl ester induces apoptosis by inhibition of NF-kB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem, 279(7), 6017-6026.
88. Wasser S. P. 2002. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol, 60, 258-274.
89. Wasser S. P. and Weis A. L. 1997. Shiitake mushroom -Lentinus edodes (Berk.) Singer. In: Medicinal Mushrooms, Nevo, E., ed. Pedelfus, Haifa, p. 45.
90. Wasser S. P. and Weis A. L. 1999a. Medicinal properties of substances occurring in Higher Basidiomycetes mushrooms: current perspectives (Review). Int J Med Mushr, 1, 31-62.
91. Wasser S. P. and Weis A. L. 1999b. General description of the most important medicinal Higher Basidiomycetes mushrooms. 1. Int J Med Mushr, 1, 351-370.
92. Wasser S. P. and Weis A. L. 1999c. Therapeutic effects of substances occurring in Higher Basidiomycetes mushrooms: a modern perespective. Crit Rev Immunol, 19, 65-96.
93. White R. and Parker M. G. 1998. Molecular mechanisms of steroid hormone action. Endocr Rel Cancer, 5, 1-14.
94. Wolff A. C. 2002. Systemic therapy. Curr Opin Oncol, 14, 600-608.
95. Xu G. 1993. Phase I clinical test report of PSP capsules. In: PSP International Symposium 1993, Yang Q. & Kwok C., eds., Fudan University Press, Hong Kong, pp. 179-182.
96. Yang Q. 1999. History, present status and perspectives of the study of Yun Zhi polysaccharopeptide. In: Advanced Research in PSP, Yang Q., ed. Hong Kong Assotiation for Health Care Ltd., pp. 5-15.
97. Yassin M., Mahajna J. A., and Wasser S. P. 2003. Submerged cultured mycelium extracts of Higher Basidiomycetes mushrooms selectively inhibit proliferation and induce differentiation of K562 human chronic myelogenous leukemia cells. Int J Med Mushr, 5, 261-276.
98. Yokoe T., Ino Y., Takei H., Horiguchi J., Koibuchi Y., Maemura M., Ohwada S., and Morishita Y. 1997. HLA antigen as predictive index for the outcome for breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res, 17, 2815-2818.
99. Yue W., Wang J. P., Hamilton C., Demers L., and Santen R. J. 1998. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res, 58, 927-932.
100. Zaidman B., Yassin M., Mahajna J., and Wasser S. P. 2005. Medicinal mushrooms modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol (in press).
101. Zandi E. and Karin M. 1999. Bridging the gap: composition, regulation, and physiological function of the IkB kinase complex. Mol Cell Biol, 19, 4547-4551.
102. Zhang Y., Bai W., Allgood V. E., and Weigel N. L. 1994. Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol, 8, 577-584.